BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects

Phase 3

Completed

Conditions: Anemia
Renal Insufficiency, Chronic

Interventions: Drug: Molidustat (BAY85-3934)
Drug: Darbepoetin alfa

First Posted Date: 2017-11-22

Last Posted Date: 2021-01-29

Lead Sponsor: Bayer

Target Recruit Count: 164

Registration Number: NCT03350347

Locations: 🇯🇵
Matsunami Health Promotion Clinic, Hashima-gun, Gifu, Japan
🇯🇵
Mazda Hospital of Mazda Motor Corporation, Aki-gun, Hiroshima, Japan
🇯🇵
Higashihiroshima Medical Center, Higashihiroshima, Hiroshima, Japan

and more 56 locations

A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects

Phase 3

Completed

Conditions: Renal Insufficiency, Chronic
Anemia

Interventions: Drug: Molidustat (BAY85-3934)

First Posted Date: 2017-11-22

Last Posted Date: 2021-01-29

Lead Sponsor: Bayer

Target Recruit Count: 25

Registration Number: NCT03351166

Locations: 🇯🇵
Houshikai Kano hospital, Kasuya-gun, Fukuoka, Japan
🇯🇵
Asahikawa-Kosei General Hospital, Asahikawa, Hokkaido, Japan
🇯🇵
Ishikari Hospital, Ishikari, Hokkaido, Japan

and more 17 locations

Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg

Phase 1

Completed

Conditions: Chagas Disease

Interventions: Drug: Nifurtimox (Lampit, BAYA2502)

First Posted Date: 2017-11-22

Last Posted Date: 2019-12-12

Lead Sponsor: Bayer

Target Recruit Count: 48

Registration Number: NCT03350295

Locations: 🇦🇷
FP Clinical Pharma, Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina

Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Acarbose
Drug: Metformin
Drug: Placebo

First Posted Date: 2017-11-21

Last Posted Date: 2020-08-05

Lead Sponsor: Bayer

Target Recruit Count: 287

Registration Number: NCT03349684

Locations: 🇨🇳
The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
Sun Yat-Sen Memorial Hosp. Sun Yat-Sen Univ., Guangzhou, Guangdong, China

and more 26 locations

Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC

Phase 1

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Regorafenib(Stivarga, BAY73-4506)
Drug: Pembrolizumab

First Posted Date: 2017-11-20

Last Posted Date: 2023-07-25

Lead Sponsor: Bayer

Target Recruit Count: 58

Registration Number: NCT03347292

Locations: 🇺🇸
USC Norris Hospital and Clinics, Los Angeles, California, United States
🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇩🇪
Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany

and more 4 locations

Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned

Phase 1

Terminated

Conditions: Leiomyoma

Interventions: Drug: Vilaprisan, BAY1002670
Drug: Ulipristal

First Posted Date: 2017-11-17

Last Posted Date: 2021-01-06

Lead Sponsor: Bayer

Target Recruit Count: 10

Registration Number: NCT03342859

Locations: 🇬🇧
Edinburgh Royal Infirmary/ NHS Lothian, Edinburgh, United Kingdom

Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study

Phase 1

Completed

Conditions: Chagas' Disease

Interventions: Drug: Nifurtimox (Lampit, BAYA2502)

First Posted Date: 2017-11-07

Last Posted Date: 2020-12-30

Lead Sponsor: Bayer

Target Recruit Count: 36

Registration Number: NCT03334838

Locations: 🇦🇷
FP Clinical Pharma, Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina

Prospective Multicenter Non-interventional Study in Patients With Knee or Hip Osteoarthritis Having a Theraflex Treatment

Completed

Conditions: Osteoarthritis

Interventions: Drug: Theraflex, BAY 874017

First Posted Date: 2017-11-06

Last Posted Date: 2021-10-14

Lead Sponsor: Bayer

Target Recruit Count: 1102

Registration Number: NCT03330288

Locations: 🇷🇺
Sci-Res Institute of Rheumatology n.a. V.A. Nasonova of RAMS, Moscow, Russian Federation
🇷🇺
Many locations, Multiple Locations, Russian Federation

Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study

Withdrawn

Conditions: Prostatic Neoplasms, Castration-Resistant

Interventions: Drug: radium Ra 223 dichloride (Xofigo, BAY88-8223)
Drug: Zytiga
Drug: Xtandi

First Posted Date: 2017-10-30

Last Posted Date: 2018-10-31

Lead Sponsor: Bayer

Registration Number: NCT03325127

Treatment Satisfaction With Ra-223 in Japan

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)

First Posted Date: 2017-10-20

Last Posted Date: 2024-02-08

Lead Sponsor: Bayer

Target Recruit Count: 85

Registration Number: NCT03315260

Locations: 🇯🇵
Many Locations, Multiple Locations, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy